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Abstract
Introduction: Aberrant signaling within and between B and T cells, considered to be central in systemic lupus erythemato-
sus (SLE), could depend on enhanced CD40-CD154 activation. As a result, autoreactive B cells, normally anergic, differen-
tiate and secrete antibodies attacking several normal tissues. Thus restorating B cell homeostasis might help control this dis-
ease. In this study, two facets of SLE B cells were investigated, namely their in vitro response to CD40-CD154 and the effect
of treatment with human immunoglobulins for intravenous use (IVIg). 
Materials and Methods: Blood samples from SLE patients and healthy volunteers were obtained and used to isolate B cells,
which were activated through CD40 in the presence or absence of IVIg. The phenotype, proliferation, and differentiation of
the SLE B cells were determined and compared with those of control B cells using flow cytometry and standard ELISA. 
Results: In this model, CD40-activated SLE B cells, as control B cells, proliferated and differentiated and were character-
ized by the emergence of CD19loCD38++CD138+CD27++ cells. IVIg treatment of the CD40-activated SLE B cells resulted
in higher differentiation, characterized by increased secretion rates of IgG and IgM, as reported previously for control
B cells. 
Conclusions: Taken as a whole, such accelerated differentiation of CD40-activated B cells suggests that IVIg may participate
in re-equilibration of the antibody repertoire by replacing pathological antibodies by de novo harmless antibodies.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex
autoimmune disease with heterogeneous clinical mani-
festations [reviewed in (Zimmerman et al. 2001)].
Lymphopenia is commonly observed in SLE manifested
by decreased numbers of T cells, including CD4+ and
CD8+ cells (Wouters et al. 2004), as well as B cells
(Odendahl et al. 2000). Homeostasis within peripheral
B cells from SLE patients is disturbed and can be charac-
terized by an increased frequency of CD27+ cells
(Odendahl et al. 2000; Jacobi et al. 2003). SLE patients
with active disease have a higher frequency of circulating
blood plasma cells (Harada et al. 1996; Jacobi et al. 2003).
Aberrant levels of soluble or surface molecules involved
in B-cell activation, such as interleukin (IL)-10, BAFF,
CD40, and CD154 (Gonzalez-Amaro et al. 1998; Sun et
al. 2000; Zouali 2005), as well as enhanced calcium
release, defective FcγRIIB signaling, and reduced expres-
sion of Lyn [reviewed in (Pugh-Bernard and Cambier
2006)] can all be observed in SLE. Overall, SLE is caused
by multiple immune dysregulations involving several cell
populations, in which B-cell dysfunction, leading to a gen-
eral B-cell hyperactivity, appears to be a central element
[reviewed in (Mandik-Nayak et al. 2008)]. 
Autoantibodies observed in the serum of SLE
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patients include IgG specific to dsDNA (Klinman et al.
1994). Anti-dsDNA antibodies from SLE patients are
often derived from the VH4-34 gene, characterized by
the 9G4 idiotype, which has been proposed as a marker
of disease severity (Cappione et al. 2004; Isenberg et al.
1998; Pugh-Bernard et al. 2001). For instance, these
anti-dsDNA antibodies are particularly associated with
renal damage (Putterman 2004), and an increased fre-
quency of CD27– memory B cells carrying the 9G4 idio-
type has recently been reported to correlate with
increased disease activity (Wei et al. 2007).
In many autoimmune disorders, IVIg treatment
results in the suppression of pathological autoimmune
antibodies in patient serum for prolonged periods of
time (Branch et al. 2001; Kaveri et al. 1991). Since IVIg
contains anti-idiotypic antibodies capable of binding to
these pathological autoantibodies, many authors have
postulated that IVIg can directly and specifically modu-
late autoreactive B cells (Kazatchkine et al. 1994; Seite
et al. 2008; Sherer and Shoenfeld 2006b; Shoenfeld and
Katz 2005; Vani et al. 2008) and by doing so restore
immune homeostasis in patients with autoimmune dis-
eases. The use of IVIg in the treatment of SLE can
result in partial to complete remission in patients with
various manifestations of SLE [reviewed in (Zandman-
Goddard et al. 2005)]; however, its use is often restrict-
ed to SLE patients who did not respond to standard
treatment (Sherer and Shoenfeld 2006a). The anti-
inflammatory properties of IVIg have been invoked to
explain its therapeutic effects in the treatment of
autoimmune diseases, including SLE (Anthony et al.
2008). Alternatively, a possible connection between the
immunomodulatory mechanisms of IVIg and SLE treat-
ment could involve blockade of BAFF through anti-
BAFF (Le Pottier et al. 2007; Toubi and Shoenfeld
2004a; Vani et al. 2008) or neutralization of pathogenic
anti-dsDNA through anti-idiotypic antibodies, as
reported in mouse models (Shoenfeld et al. 2002).
In the course of an immune response, B cells prolif-
erate and form germinal centers in lymph nodes
(McHeyzer-Williams et al. 2006). This step requires the
stimulation of CD40 expressed on B cells by its ligand
CD154 expressed on activated T cells (Van Kooten and
Banchereau 2000). There is good evidence that dysfunc-
tion in the CD40-CD154 interaction contributes to SLE
pathogenesis (Grammer et al. 2003; Toubi and
Shoenfeld 2004b), as demonstrated in clinical trials
investigating treatment with humanized anti-CD154
antibodies, even though these trials have not been suc-
cessful due to adverse side effects (Driver et al. 2008).
In humans, the study of B-cell activation via CD40
can be done using an in vitro model based on feeder cells
stably transfected with CD154 supplemented with
cytokines (Banchereau et al. 1991; Néron et al. 2005).
We previously showed that IVIg modulates the prolifer-
ation and differentiation of CD40-activated human
B cells and observed IVIg-specific enhancement of
secreted anti-dsDNA and anti-IgG F(ab’)2 fragments
(de Grandmont et al. 2003). Here we report that in vitro
CD40 activation of B cells from SLE patients leading to
high expansion and differentiation can also be modulat-
ed by IVIg treatment, resulting in decreased prolifera-
tion and increased differentiation into Ig-secreting cells.
MATERIALS AND METHODS
SLE patients
Eligible subjects were adult women or men, aged
≥18 years, who met the American College of
Rheumatology criteria for the definition of SLE
(Gladman et al. 2000). Disease activity in these patients
was defined using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) on the day of blood
collection ( Hawker et al. 1993; Hochberg 1997;
Gladman et al. 2000; Liang et al. 1989). Organ damage
resulting from SLE was assessed according to the
ACR/SLICC Index (Gladman et al. 2000). Treatments
received by each patient were noted on the day of blood
collection; no exclusions based on treatment allocation
(e.g. cyclophosphamide or prednisone) were made in
this study.
Blood sample collection from SLE patients 
and healthy individuals
Blood samples were collected from SLE patients
after informed consent following approval by the
Research Ethics Board of the Centre hospitalier univer-
sitaire de Sherbrooke and the Research Ethics
Committee of Héma-Québec. Whole blood samples
were collected from SLE patients in heparinized tubes
(Vacutainer, Becton Dickinson, Franklin Lakes, NJ,
USA). A maximum of 14 tubes from each patient were
collected, pooled, and diluted in one volume of 10 mM
phosphate-buffered saline, pH 7.4. Leukocytes from
healthy individuals were recovered from leukoreduction
systems, as described previously (Néron et al. 2006;
Néron et al. 2007), after informed consent and following
approval by the Research Ethics Committee of Héma-
Québec. Peripheral blood mononuclear cells (PBMCs)
were prepared from patients and controls by density
centrifugation over Ficoll-Paque (GE Healthcare Bio-
-Sciences Inc., Baie d’Urfé, QC, Canada) (Fecteau and
Néron 2003) and stored frozen until B-cell purification.
About 50–100×106 cells were recovered from each SLE
sample. 
CD40 stimulation of peripheral B cells
B cells were purified as described previously (Néron
et al. 2005) and seeded at 300,000 cells/ml in Primaria
plates (Becton Dickinson) in the presence of γ-irradiat-
ed L4.5 cells expressing CD154 (Néron et al. 1996; Roy
et al. 2001). About 5 or 25 B cells were seeded per L4.5
cell to achieve high and low levels of CD154-CD40
interaction (Néron et al. 2005), respectively, in the pres-
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ence of 50 U/ml IL-2, 25 U/ml IL-10 (PeproTech, Rocky
Hill, NJ, USA), 100 U/ml IL-4 (R&D Systems,
Minneapolis, MN, USA) and, where indicated, 25 ng/ml
BAFF (PeproTech). Viable cell counts were evaluated
in triplicate by Trypan blue dye exclusion using a hema-
cytometer.
Intravenous immunoglobulin preparations
GamunexTM intravenous immunoglobulin prepara-
tion (IVIg) from Bayer Inc. (Toronto, Ont., Canada)
and bovine serum albumin (BSA, Cohn fraction V,
Sigma, St. Louis, MO, USA) were dialyzed against 10
mM potassium/sodium phosphate with 136 mM NaCl
(Invitrogen) containing 40 mM glycine, pH 4.5 (Sigma)
(de Grandmont et al. 2003; Dussault et al. 2008). BSA,
which does not interfere with B-cell proliferation and Ig
secretion (de Grandmont et al. 2003), was used as a con-




jugated anti-CD19, anti-CD21, or anti-CD38, PE-conju-
gated anti-CD27, anti-CD40, or anti-CD138, FITC-con-
jugated anti-CD27 or anti-IgG, and the PerCP-cyanin
5.5-, allophycocyanin-, PE-, and FITC-conjugated iso-
type controls were IgG1 mouse mAbs obtained from BD
Biosciences (Mountain View, CA, USA). The VH4-34-
-specific anti-idiotype mAb 9G4, kindly provided by Dr.
Freda Stevenson (Tenovus Research Laboratories,
Southampton, UK), was used in indirect staining with
FITC-conjugated goat F(ab’)2 anti-rat IgG. Cells were
fixed with 2% paraformaldehyde and >95% of the cells
were double-negative with isotype-matched control
Abs. Intracellular IgG content was determined on fixed
cells permeabilized with 0.1% saponin. Dot-plot regions
containing dead cells were delineated using 7-amino-
-actinomycin D staining following the manufacturer’s
instructions (BD Bio-sciences) and all analyses were
done on viable cells only. Data acquisition was done by
gating >80,000 cells for PBMCs or >5000 for purified
B cells with a FACSCalibur flow cytometer and
CellQuest Pro software (BD Biosciences). Data were
subsequently analyzed using FCS express II (De Novo
Software, Thornhill, ON, Canada).
IgG and IgM secretion rates
B cells were harvested and extensively washed using
10 mM phosphate-buffered saline, pH 7.4. For IVIg-
-treated cells, the assayed IgG and IgM concentrations
in the last washing supernatants were found to be negli-
gible in all cases (<5–10 ng/ml/h). Cells were seeded at
1–2×106 cells/ml in IMDM medium without added
cytokines and CD154-expressing cells for 6–24 h. IgG
and IgM concentrations were determined using a stan-
dard ELISA (Fecteau and Néron 2003).
Statistical analysis
The mean values ±SD were calculated for the
groups of SLE patients and healthy controls (HC). The
data distribution was evaluated using the Shapiro-Wilk
test and analysis of variance was done using the F test.
Thereafter, statistical significance between patients and
controls was determined using the Mann-Whitney
U test, two-sided Student’s unpaired t test, or the
Satterthwaite test.
RESULTS
SLE peripheral blood B cells respond 
to low CD154 interaction 
To study the response of SLE B cells to in vitro CD40
stimulation, we applied conditions that allow the expan-
sion and differentiation of both naïve and memory
B cells (Néron et al. 2005). Purified B cells obtained
from 12 SLE patients were stimulated under conditions
of low CD40-CD154 interaction in the presence of
a mixture of IL-2, IL-4, and IL-10 for 9–14 days (Table
1, n=12). All the samples tested responded to CD40
activation by proliferation, as shown by Tgen ranging
from 29–77 h. In addition, the viability of the activated
B cells was maintained above 79% in all assays. Under
these conditions, Tgen and viability of the SLE samples
were not significantly different from those of the B cells
from the HC. No obvious correlation could be discerned
between disease severity, which was generally moderate
(SLEDAI ≤9), and the level of SLE B-cell response to
CD40 stimulation. The diverse medication regimens
administered to the SLE patients did not influence the
response capacity of their B cells in culture. Three rep-
resentative examples of the results presented in Table 1
(sample no. 5, 17, and 19) illustrating the expansion of
SLE B cells compared with HC B cells are shown in Fig.
1. For all 12 samples listed in Table 1, the SLE B cells
showed proliferation similar to that observed for the HC
cells when maintained for culture periods of 9 or 13
days. The SLE B cells were characterized by elevated
IgG and IgM secretion rates (Fig. 1B) which were at
least similar to or higher than those of HC B cells.
Overall, under these culture conditions the IgG secre-
tion rates of the SLE B cells were about 8-fold higher
than those of IgM, reaching 1 µg/106-cells/h. These
observations suggest that SLE B lymphocyte activation
status was somewhat similar to that of the control cells.
The SLE samples (Fig. 1C) showed higher frequencies
of CD27+ cells than the HC samples after long-term
stimulation, indicating a possible bias in the SLE B lym-
phocyte populations. Overall, these observations sug-
gest that the in vitro response of SLE B cells to CD40
activation might represent a good reflection of their in
vivo activation status, characterized by high Ig secretion
and a sustained CD40-dependent proliferative
response. 
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CD138+ cells are present at high frequencies 
in mononuclear cells from SLE patients with low 
to moderate disease activity
High frequencies of CD27+, CD38++, and CD138+
cells are observed in patient blood showing highly active
SLE disease (Harada et al. 1996; Odendahl et al. 2000;
Sato et al. 2004). In this study, the disease severity of most
of the SLE participants was moderate (SLEDAI ≤9), with
only a few cases reaching a level of 12. Despite the limit-
ed number of severe cases, given the relevance of these 
B-cell differentiation markers we determined the fre-
quencies of CD19-, CD27-, CD38-, and CD138-positive
cells within the PBMCs of 10 SLE patient samples by flow
cytometry (Table 2). The frequencies of CD19+ cells and
CD27+ B cells, ranging respectively from 2–15% and
15–48%, were not significantly different from the values
obtained with HC cells and similar to those previously
reported for healthy individuals (Néron et al. 2006). In
contrast, the frequency of CD138+ cells, ranging from
1.4–10%, was well above normal ranges (p<0.002) com-
pared with HC (0.5±0.4%), which were close to the
expected normal frequency of 0.5% (Harada et al. 1996).
These CD138+ cells expressed CD27 at intermediate lev-
els (mean fluorescence intensity, MFI: 35±15) and a frac-
tion of the cells (6–43%) maintained CD19 expression,
indicating that the cells were in transition toward final dif-
ferentiation. Worthy of note, only a fraction (44±10%) of
the CD138+ cells present in the HC samples expressed
CD27. In addition, the proportion of B cells expressing
high levels of CD38 was also significantly higher
(p<0.008) in SLE (15±10%) than in HC (5±4%). These
observations suggest that the presence of CD27+CD138+
and CD38++ cells at higher frequencies is a distinctive
feature of SLE peripheral blood cell populations, even in
patients with moderate disease activity. 
SLE B cells show a low level of differentiation 
into CD138+ cells
We previously reported that a low level of CD40 acti-
vation can drive B cells toward differentiation into plas-
ma cells expressing CD138 (Néron et al. 2005). To fur-
ther investigate CD138+ cell populations in vitro, CD40-
-induced responses of SLE B cells from three patients
with the respective SLEDAIs of 0, 8, and 12 were com-
pared with those of control cells exposed to the same
conditions for nine days, after which CD19, CD27, and
CD138 expression was determined by flow cytometry
(Fig. 2). As previously reported (Néron et al. 2005), in
vitro activation of HC B cells using a low level of CD40
stimulation in the presence of a mixture of IL-2, IL-4,
and IL-10 resulted in high proportions of CD27+ (33%)
and CD138+ (23%) cells. Likewise, CD27 and CD138
frequency appeared lower in SLE B cells than in HC
B cells, ranging from 7–19% and 1–9%, respectively (Fig.
2A). However, CD38++CD138+ cells, as defined by gate
2 in Fig. 2, were also CD27+CD19lo and thus correspond
Table 1. B cells isolated from PBMCs obtained from patients with SLE proliferate in response to sustained CD40 activation
Patients Disease activity indices3 CD40 activation4
No. Criteria1 Treatment2 SLEDAI ACR/SLICC Viability Tgen
(%) (h)
1 8 A, C, I 6 0 88±4 65
2 4 A, O 2 0 81±6 61
5 7 A, C, I, O 5 1 89±6 46
9 6 A, C, I, O 8 6 88±6 57
10 6 A, I, O 0 1 79±6 39
11 6 A, O 0 0 88±7 74
12 4 O 2 0 91±4 36
17 5 A, C, O 0 0 94±3 77
19 4 A, O 0 0 85±10 33
24 7 A, I, 3 ND 91±3 9
26 4 O 0 3 88±5 68
32 7 A, I, O 9 1 90±6 29
SLE (n=12)5 – 88±6 53±16
HC (n=12)5 – 90±9 52±24
1 Number of criteria according to the American College of Rheumatology classification (Hochberg 1997); ND: not determined.
2 Treatments are designated as immunosuppressant (I) such as azathioprine, cyclosporine or mycophenolate mofetil, corticos-
teroids (C) (mainly prednisone), antimalarial (A) (mainly hydroxychloroquine sulphate), and others (O).
3 SLEDAI: disease activity indices (Hawker et al. 1993; Liang et al. 1989); ACR/SLICC Assessment of organ damage (Gladman et
al. 2000).
4 CD19+ B cells were exposed to a low level of CD154 stimulation in the presence of IL-2, IL-4, and IL-10 for 9 to 14 days. The
average viability (%) of stimulated cells is shown and the generation time (tgen) was calculated within the exponential phase of the
growth curve using the formula κ=1/ln2 (ln[Nt2]–ln[Nt1])/t2–t1 and tgen=1/κ
5 Mean values for generation time and viability are given for SLE and healthy control (HC) B cells and are not significantly differ-
ent from each other according to Student’s t test.
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Fig. 1. CD40 activation of B cells from SLE patients induces high and
sustained IgG and IgM secretion. B cells isolated from healthy controls
(HC) or SLE patients were stimulated under conditions of low CD154
interaction in the presence of a mixture of IL-2, IL-4, and IL-10 for 14
days. (A) Cell counts were determined on the indicated days and used to
evaluate total expansion, taking into account the expansion rate and the
seeding cell density. These three paired sets of HC and SLE cultures
were done at different times. Viability was >90% for all samples
throughout the culture period. SLE samples in this assay were from
patient no. 5, 17, and 19, (cf. Table 1). (B) IgG and IgM secretion rates
were measured at the end of the culture period using samples from SLE
patient no. 5 and 19 and paired HC, over 5 and 4 h, respectively. Error
bars for triplicate values can be smaller than symbols. This tendency was
also observed in a supplemental paired culture of HC and SLE using
samples from patient no. 23 (cf. Table 2). (C) B-cell phenotypes were
compared on days 8 to 9 (samples from patient no. 24 and 26) or 13 to
14 (samples from patient no. 5 and 17) according to CD19 and CD27















































Table 2. High frequencies of CD138+CD27+ cells within PBMCs in the samples from SLE patients
Patients1 PBMC2 (% positive) CD19+ cells3 (%) CD138+CD27+ cells4
No. SLEDAI ACR CD19 CD138 CD27 CD38 CD38hi CD19 CD27
(MFI) (%) (MFI)
3 0 7 5 1.4 38 66 21 (263) 14 47
6 8 6 5 10 23 42 11 (375) 5 26
14 4 4 4 3 48 50 3 (347) 6 34
15 0 5 4 8 37 48 26 (501) 5 51
16 8 7 10 7 41 46 11 (313) 12 54
21 4 7 13 8 18 86 24 (202) 8 43
22 4 5 2 2 25 77 13 (281) 6 47
23 12 7 4 3 27 69 4 (225) 43 14
24 3 7 8 2 15 66 29 (205) 33 22
25 6 6 2 2 33 30 4 (176) 22 13
SLE (n=10)5 6±4 5±3 31±11 58±18 15±10 15±13 35±15
Mean±SD 
HC (n=10)5 9±4 0.5±0.4 31±12 64±16 5±4 17±10 NA
Mean±SD 
1 Disease activity indices and number of criteria according to ACR as reported in Table 1.
2 Frequencies of B cells (CD19+) and plasma cells (CD138+) in PBMCs were determined by flow cytometry. 
3 The proportion of cells expressing CD27, CD38, as well as a high level of CD38 (CD38hi) were determined within the gated
CD19+ cell population. MFI: mean fluorescence intensity.
4 CD138+ cells from SLE samples all expressed CD27 (100%); the proportion of CD19 (%) as well as the level of CD27 expres-
sion (MFI) within CD138+ cells are shown.
5 Mean and SD for SLE and healthy controls (HC) samples are shown for each cell subset. Significant differences between SLE
and HC were observed for the frequencies of CD138+ cells (p<0.0002) and CD38high (p<0.008). NA: not applicable, since
44±10% of the CD138+ cells from HC expressed CD27 (MFI; 102±22), as opposed to 100% of cells from SLE patients; this dif-
ference is statistically significant (p<0.0001), as determined by the Mann-Whitney test. 
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to CD19loCD27+CD38++CD138+ cells in both HC and
SLE samples. Collectively, these observations indicate
that CD40-activated SLE B cells can differentiate into
CD138+ cells in vitro; however, the proportion of
CD138+ cells obtained after 8–9 days of culture of SLE
B cells was lower than that of HC, which is in contrast to
the high frequencies of CD138+ cells observed in the
peripheral blood of SLE patients (Harada et al. 1996;
Odendahl et al. 2000; Sato et al. 2004). 
SLE B-cell proliferation and differentiation 
are both modulated in vitro by the addition 
of therapeutic immunoglobulins
Intravenous immunoglobulin injection to patients at
doses of 0.4–2 g/kg generally gives rise to an increase in
IgG blood concentration of about 5–10 mg/ml (Morell
1997; Negi et al. 2007). Based on our previous observa-
tions (de Grandmont et al. 2003; Dussault et al. 2008),
SLE and HC B cells were treated with 10 mg/ml thera-
peutic immunoglobulin preparation (IVIg) using BSA
as the protein supplement control (Fig. 3). To visualize
whether there was a difference related to the level of
activation, cell culture was performed under conditions
of high CD40 stimulation in the presence of IL-4 alone
(Fecteau and Néron 2003) and with low CD40 stimula-
tion in the presence of IL-2, IL-4, and IL-10 (Néron et
al. 2005). Overall, IVIg inhibited the expansion of HC
and SLE B cells under both the high (2- to 4-fold) and
low (1.5- to 2.5-fold) CD40 stimulation conditions (Figs.
3A and B). Compared with HC B cells, SLE B cells
showed higher secretion of IgG and IgM by a factor of
up to 6-fold under both conditions. The inhibitory
effects of IVIg on cellular expansion can in fact be asso-
ciated with enhanced IgM and IgG secretion rates (Figs.
3C and D). Indeed, IVIg-induced modulation of IgG
secretion was about 5-fold and 3-fold in cells receiving
high and low CD40 stimulation, respectively, for both
control and SLE B cells. Additionally, the effect of IVIg
on IgM secretion appeared higher for SLE B cells (3-
-fold) compared with controls (<1.7-fold) (Fig. 3C).
Overall, these observations show that in vitro treatment
of SLE B cells with IVIg results in decreased prolifera-
tion and increased differentiation, as previously report-
ed for B cells from healthy individuals (de Grandmont
et al. 2003).
The frequency of CD138+ cells is slightly increased 
following IVIg treatment
B cells stimulated under conditions of low CD40
interaction, as defined above, were then monitored for
the emergence of CD138+ cells following treatment
with IVIg (Fig. 4). The frequency of CD138+ cells, of
phenotype CD19loCD27+CD38++ as specified in Fig. 2,
was slightly increased when SLE and HC B cells were
treated with IVIg. The CD38+ and CD27+ populations
were also increased to a similar extent in both SLE and
HC B cells. Although interindividual differences were
observed, these results indicate that IVIg treatment
might modulate a small fraction of B cells to differenti-
ate into Ig-secreting cells. 
IVIg treatment increases the proportion of 9G4+ cells 
in SLE and control B cells
The 9G4 idiotype characterizes a small population
of B cells that are often linked to anti-dsDNA antibod-
ies in SLE (Anolik et al. 2004; Isenberg et al. 1998). SLE
disease is also characterized by sustained lymphocyte
stimulation, based on a high CD154 expression on
T cells (Toubi and Shoenfeld 2004b) as well as an
increased concentration of BAFF (Tangye et al. 2006;
Zhang et al. 2001). Based on these studies, we further
investigated the effect of IVIg treatment on B cells
Fig. 2. The emergence of CD138+ cells following long-term stimu-
lation of SLE B cells does not correlate with disease activity index.
B cells isolated from a healthy control (A) or SLE patient nos. 26
(B), 9 (C), and 23 (D) with the respective SLEDAIs of 0, 8, and 12
were stimulated as described in Fig. 1 for 8 days. Cell phenotypes
according to CD19, CD27, CD38, and CD138 were determined by
quadruple-staining flow cytometry as described in Materials and
Methods. On the day of sample collection, patient no. 9 was treat-
ed with mycophenolate mofetil and hydroxychloroquine sulfate,
patient no. 23 with hydroxychloroquine sulfate and prednisone, and
patient no. 26 only received anticoagulants. The events delineated
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under conditions of high CD40 stimulation in the pres-
ence of a mixture of IL-2, IL-4, IL-10, and BAFF and
monitored the proportion of 9G4+ cells in three inde-
pendent experiments (Fig. 5). As above (Fig. 3), the
expansion of the IVIg-treated SLE B cells was reduced
by at least 2-fold over the 14-day culture period (Fig.
5A), while IgM secretion rates were increased by about
2-fold (Fig. 5B). Under these conditions, IgG secretion
by SLE and HC B cells was equivalent to that of IgM
(100–200 ng/106 cells/h) but was not influenced by IVIg
treatment (p>0.05, data not shown). Once more, these
IVIg-dependent modulations of expansion and secre-
tion were also observed in HC B cells. However, flow
cytometry analyses showed that the frequency of cells
expressing the 9G4 idiotype was increased by about 2-
and 4-fold for SLE and HC B cells, respectively, follow-
ing IVIg treatment. Such IVIg-induced differences in
the frequency of B cells expressing the 9G4 idiotype
were significant in four independent experiments for
both HC (p<0.005) and SLE (p<0.01) B cells. More
specifically, IVIg-treated SLE and HC B cells showed
29±14% and 32±11% 9G4+ cells, respectively, while
untreated SLE and HC B cells showed about 9±3%
9G4+ cells. We also observed that the mean fluores-
cence intensity for 9G4 expression significantly
decreased following IVIg addition (p<0.005, data not
shown). These trends suggest that IVIg treatment of
human B cells could induce changes inside the 9G4+
populations. 
DISCUSSION
Abnormal CD40-CD154 interaction between B and
T cells is considered to be an important determinant of
SLE disease severity (Grammer and Lipsky 2002; Toubi
and Shoenfeld 2004b). In vitro treatment of SLE B cells
with recombinant trimeric CD154 used as a single agent
results in attenuated proliferation and higher Ig secre-
tion compared with control B cells grown under similar
conditions (Harigai et al. 1999). In this study we per-
formed long-term activation of SLE B cells using inter-
action with CD154+ cells and cytokines. Our observa-
tions suggest that following CD154 stimulation, the
long-term expansion and differentiation into CD138+
cells of SLE B cells can be quite similar to that of B cells
from healthy individuals. Such in vitro similarities sup-
port the hypothesis that SLE B-cell dysregulation
depends on cooperation with other cells in their envi-
ronment when CD40-CD154 binding is provided with-
out restriction. 
In contrast, IgM and IgG secretion by SLE B cells
was, in many cases, higher than that of control B cells
when exposed to either a low or a high level of CD40
stimulation. In addition, the frequency of CD27+ cells
was higher in SLE B cells following long-term stimula-
tion. These observations are in agreement with previous
studies on SLE reporting higher frequencies of CD27+
blood B cells and plasma cells (Arce et al. 2001; Jacobi
et al. 2003; Odendahl et al. 2000), which could be prone
to rapid differentiation into Ig-secreting cells through
Fig. 3. IVIg treatment modulates the
proliferation and differentiation of
SLE B cells. Purified B cells were
exposed to conditions of high CD154
interaction in the presence of IL-4
alone or low CD154 interaction in
the presence of a mixture of IL-2, IL-
-4, and IL-10 for 13 days with or
without 10 mg/ml IVIg, as indicated.
Expansion of B cells from (A)
healthy controls (HC) or (B) an SLE
patient (no. 17) was determined on
the indicated days. Viability was
>90% for all samples during the cul-
ture period. The same tendency
were observed in an independent
experiment done with samples from
two other patients. IgG and IgM
secretion rates were measured over
22 h for cells exposed to (C) high or
(D) low CD154 conditions. The
results in panels (C) and (D) are rep-
resentative of the tendency observed
in two other independent experi-
ments done with samples from dif-
ferent patients with SLEDAIs ≤12.
The B cells used in B, C, and D were
obtained from patient no. 17, 11, and
23 with SLEDAIs of 0, 0, and 12,
respectively. Error bars can be small-
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CD40-CD154 interaction (Nagafuchi et al. 2003).
Collectively, our observations indicate that the in vitro
model making use of CD154+ cells as a surrogate for
activated T cells (Van Kooten and Banchereau 2000),
supplemented with cytokines, could be used to further
investigate SLE B cells in the context of a high CD40
stimulus. 
Additionally, as previously observed for normal
B cells (de Grandmont et al. 2003), the proliferation and
differentiation of SLE B cells were modulated by in vitro
IVIg treatment. The comparison of IVIg treatment on
HC and SLE B cells exposed to low and high levels of
CD154 stimuli showed that proliferation was reduced,
whereas IgG secretion rates increased in all the tested
samples in the presence of IL-2, IL-4, and IL-10.
Considerable evidence points to the inhibitory receptor
FcγRII (CD32) as an important cellular target of IVIg
action (Nimmerjahn and Ravetch 2008); however, sig-
naling through this negative Fc receptor is defective in
SLE patients [reviewed in (Pugh-Bernard and Cambier
2006)]. As postulated before (de Grandmont et al. 2003;
Dussault et al. 2008), IVIg could interact with other
receptors on SLE B cells, possibly triggering their dif-
ferentiation toward IgG secretion. A modest IVIg-
-induced enhancement of differentiation into
CD38++CD138+ cells is reported here for both SLE and
control B cells. This observation required a low level of
CD154 stimulation, since a high level of stimulation
does not allow the emergence of CD138+ cells (Néron
et al. 2005). In line with these results, the frequency of
9G4+ cells was also modulated following in vitro IVIg
treatment of both control and four SLE samples.
Transposed to the in vivo situation, where resources for
survival following first-step activation are limited
(Agenes et al. 2000), these observations suggest that
anti-idiotypic antibodies present in IVIg could bind to
Fig. 4. IVIg modulates CD138+ cells in control and SLE B cells. B cells isolated from a healthy control (A, C) or SLE patients with the
respective SLEDAIs of 3 (B) and 12 (D) were stimulated as described in Fig. 1 for 9 days in the absence or presence of 10 mg/ml IVIg. Cell
phenotypes according to CD19, CD27, CD38, and CD138 were determined using quadruple-staining flow cytometry as described in
Materials and Methods. As in Fig. 2, the cells defined by gate 2 were CD19loCD27+CD38++CD138+. 
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9G4+ autoreactive B cells and favor their deletion, as
demonstrated in an SLE mouse model (Shoenfeld et al.
2002).
This study revealed for the first time that IVIg could
act on SLE B cells under conditions of either low or high
CD40 stimulus in the presence of IL-4 alone or in com-
bination with IL-2 and IL-10. Furthermore, the effects
of IVIg were observed even when BAFF (also known as
BLyS), which is considered to be an important element
in SLE pathology (Carter et al. 2005), was added to the
cytokine cocktail. BAFF levels are elevated in the serum
of SLE patients (up to 20 ng/ml) (Cambridge et al. 2006;
Zhang et al. 2001) and an IVIg-induced reduction in
proliferation was observed even when SLE B cells were
stimulated in the presence of similarly elevated BAFF
concentrations (25 ng/ml). 
Short- and long-lived plasma cells secreting patho-
genic autoantibodies are an important target for the
treatment of SLE (Dilillo et al. 2008; Grammer and
Lipsky 2003; Radbruch et al. 2006). The fact that IVIg
increased differentiation of SLE B cells toward plasma
cells might seem contradictory. Interestingly, a recent
study reporting that IVIg promotes immature plasma
cell mobilization also showed that this was also a favor-
able prognostic marker for patients with Guillain-Barré
syndrome and correlated with improved neurological
function (Mori et al. 2008). These authors proposed that
IVIg treatment induced a wave of newly formed plasma
cells which can enter into competition with older plasma
cells and re-equilibrate the repertoire of circulating
antibody with nonpathogenic antibodies. Our results
showing increased in vitro differentiation of B cells fol-
lowing IVIg treatment support their in vivo observations
and are in agreement with their hypothesis. Therefore,
these de novo IVIg-induced antibodies might further
help in controlling the reactivities of pathogenic autoan-
tibodies either by sequestering autoantigens or by mech-
anisms involving an idiotypic network, as proposed else-
where (de Grandmont et al. 2003; Seite et al. 2008; Tha-
-In et al. 2008; Vani et al. 2008). 
Overall, the in vitro CD40 activation system can be
used as a model to further investigate the IVIg-induced
modulation of SLE B cells. IVIg is usually administered
as a salvage therapy for SLE patients who did not
respond to standard treatment (Toubi et al. 2005; Sherer
and Shoenfeld 2006a). Here we showed that IVIg can act
on SLE B cells following their in vitro stimulation under
conditions of high exposure to CD154, a system mimick-
ing a hallmark of SLE in which sustained CD154 expres-
sion on T cells is observed (Koshy et al. 1996). Based on
the observations described here, this in vitro model could
be used to further investigate the role of IVIg-treated
B cells in the modulation of various immune-cell popu-
lations, including plasma cells.
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